Synthesis

合成
  • 文章类型: Journal Article
    背景:COVID-19大流行给个人和家庭带来了额外的心理健康负担,导致广泛的服务访问问题。数字心理健康干预措施有望改善可访问性。最近的评论显示了个人使用的新证据和多用户的早期证据。然而,数字心理健康干预措施的流失率仍然很高,和额外的复杂性存在时,多个家庭成员在一起。
    目标:因此,本范围审查旨在详细介绍为家庭使用设计的数字心理健康干预措施的报告证据,重点是促进可访问性和参与度并使家庭共同完成的构建和设计特征。
    方法:MEDLINE系统文献检索,Embase,PsycINFO,WebofScience,对2002年1月至2024年3月以英语发表的文章进行了和CINAHL数据库。合格的记录包括对数字平台的实证研究,其中包含一些旨在由相关人员共同完成的元素,以及一些旨在在没有治疗师参与的情况下完成的组件。已记录临床证据的病例包括平台。
    结果:在所审查的9527篇论文中,85(0.89%)符合资格标准。总共确定了24个供相关方共同使用的独特平台。参与者之间的关系包括夫妻,父子二元组合,家庭照顾者护理接受者,和家庭。常见的平台功能包括通过结构化干预来交付内容,而无需提供最少的剪裁或个性化。一些干预措施提供了与治疗师的现场接触。用户参与度指标和调查结果各不相同,包括用户体验,满意,完成率,和可行性。我们的发现对于文献中没有的比现在的更显著。与预期相反,很少有研究报告任何设计和建造特征,使联排。没有研究报告关于实现共同完成的平台功能或确保个人隐私和安全的考虑因素。没有人检查平台构建或设计特征作为干预效果的调节者,没有人对平台本身进行形成性评估。
    结论:在数字心理健康平台设计的早期时代,这项新颖的评论表明,与多个相关用户在治疗过程的任何方面的成功参与相关的设计元素的信息明显缺失。在详细介绍和评估平台设计的文献中仍然存在很大差距,突出未来跨学科研究的重要机会。这篇综述详细介绍了开展此类研究的动机;提出了构建供家庭使用的数字心理健康平台时的设计考虑因素;并为未来的发展提供了建议,包括平台协同设计和形成性评价。
    BACKGROUND: The COVID-19 pandemic placed an additional mental health burden on individuals and families, resulting in widespread service access problems. Digital mental health interventions suggest promise for improved accessibility. Recent reviews have shown emerging evidence for individual use and early evidence for multiusers. However, attrition rates remain high for digital mental health interventions, and additional complexities exist when engaging multiple family members together.
    OBJECTIVE: As such, this scoping review aims to detail the reported evidence for digital mental health interventions designed for family use with a focus on the build and design characteristics that promote accessibility and engagement and enable cocompletion by families.
    METHODS: A systematic literature search of MEDLINE, Embase, PsycINFO, Web of Science, and CINAHL databases was conducted for articles published in the English language from January 2002 to March 2024. Eligible records included empirical studies of digital platforms containing some elements designed for cocompletion by related people as well as some components intended to be completed without therapist engagement. Platforms were included in cases in which clinical evidence had been documented.
    RESULTS: Of the 9527 papers reviewed, 85 (0.89%) met the eligibility criteria. A total of 24 unique platforms designed for co-use by related parties were identified. Relationships between participants included couples, parent-child dyads, family caregiver-care recipient dyads, and families. Common platform features included the delivery of content via structured interventions with no to minimal tailoring or personalization offered. Some interventions provided live contact with therapists. User engagement indicators and findings varied and included user experience, satisfaction, completion rates, and feasibility. Our findings are more remarkable for what was absent in the literature than what was present. Contrary to expectations, few studies reported any design and build characteristics that enabled coparticipation. No studies reported on platform features for enabling cocompletion or considerations for ensuring individual privacy and safety. None examined platform build or design characteristics as moderators of intervention effect, and none offered a formative evaluation of the platform itself.
    CONCLUSIONS: In this early era of digital mental health platform design, this novel review demonstrates a striking absence of information about design elements associated with the successful engagement of multiple related users in any aspect of a therapeutic process. There remains a large gap in the literature detailing and evaluating platform design, highlighting a significant opportunity for future cross-disciplinary research. This review details the incentive for undertaking such research; suggests design considerations when building digital mental health platforms for use by families; and offers recommendations for future development, including platform co-design and formative evaluation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    硫酸化是对包括多糖在内的各种生物活性小分子发生的最重要的修饰之一。蛋白质,黄酮类化合物,和类固醇。反过来,这些硫酸化分子在包括细胞信号传导在内的各种过程中具有重要的生物学和药理学作用,调节免疫和炎症反应,抗凝,抗动脉粥样硬化,和抗粘合性能。这篇论文总结了遇到最多的小分子化学硫酸化方法。使用三氧化硫胺/酰胺络合物的硫酸化反应是碳水化合物中醇和酚基团最常用的方法,类固醇,蛋白质,和相关的脚手架。尽管这些方法有效,他们遭受的问题包括多个纯化步骤,毒性问题(例如,吡啶污染),净化挑战,试剂的化学计量过量导致反应成本增加,以及试剂和产品的内在稳定性问题。包括SuFEx在内的最新进展,原位试剂法,和TBSAB显示了新型硫酸化方法的广泛吸引力,通过简化纯化和分离过程以获取定制的硫酸化小分子,该方法将在未来几年内对该领域进行更大的探索。
    Sulfation is one of the most important modifications that occur to a wide range of bioactive small molecules including polysaccharides, proteins, flavonoids, and steroids. In turn, these sulfated molecules have significant biological and pharmacological roles in diverse processes including cell signalling, modulation of immune and inflammation response, anti-coagulation, anti-atherosclerosis, and anti-adhesive properties. This Essay summarises the most encountered chemical sulfation methods of small molecules. Sulfation reactions using sulfur trioxide amine/amide complexes are the most used method for alcohol and phenol groups in carbohydrates, steroids, proteins, and related scaffolds. Despite the effectiveness of these methods, they suffer from issues including multiple-purification steps, toxicity issues (e.g., pyridine contamination), purification challenges, stoichiometric excess of reagents which leads to an increase in reaction cost, and intrinsic stability issues of both the reagent and product. Recent advances including SuFEx, the in situ reagent approach, and TBSAB show the widespread appeal of novel sulfating approaches that will enable a larger exploration of the field in the years to come by simplifying the purification and isolation process to access bespoke sulfated small molecules.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    基于高尔基体α-甘露糖苷酶II(GMII)抑制的新型抗癌疗法的开发受到溶酶体α-甘露糖苷酶的不希望的共抑制的严重阻碍。在这一贡献中,我们描述了作为GMII的高度有效和选择性抑制剂的(5S)-5-[4-(卤代)苄基]苦参素的完全立体选择性合成。合成从以前报道的醛开始,容易从l-核糖获得,关键特征包括具有底物控制的立体选择性的分子内还原胺化和通过同位取代的苄基的后期衍生化。发现这些新型苦豆素类似物是高尔基型α-甘露糖苷酶AMAN-2(Ki=23-75nM)的纳摩尔抑制剂,其选择性优于溶酶体型杰克豆α-甘露糖苷酶。最后,进行了分子对接和pKa计算,以提供对抑制剂结构的更多了解:酶复合物,并进行了对相互作用能分析(FMO-PIEDA),以合理化观察到的抑制剂的效力和选择性。
    Development of novel anti-cancer therapeutics based on Golgi α-mannosidase II (GMII) inhibition is considerably impeded by an undesired co-inhibition of lysosomal α-mannosidase leading to severe side-effects. In this contribution, we describe a fully stereoselective synthesis of (5S)-5-[4-(halo)benzyl]swainsonines as highly potent and selective inhibitors of GMII. The synthesis starts from a previously reported aldehyde readily available from l-ribose, and the key features include an intramolecular reductive amination with substrate-controlled stereoselectivity and a late-stage derivatisation of the benzyl group via ipso-substitution. These novel swainsonine analogues were found to be nanomolar inhibitors of the Golgi-type α-mannosidase AMAN-2 (Ki = 23-75 nM) with excellent selectivity (selectivity index = 205-870) over the lysosomal-type Jack bean α-mannosidase. Finally, molecular docking and pKa calculations were performed to provide more insight into the structure of the inhibitor:enzyme complexes, and a pair interaction energy analysis (FMO-PIEDA) was carried out to rationalise the observed potency and selectivity of the inhibitors.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    利用羰基作为起始反应点,合成了Nootkatone的环扭曲类似物集合,包括6个CTD(复杂到多样性)化合物和9个SAR(结构活性关系)化合物。
    A collection of ring distorted analogue of Nootkatone including 6 CTD (Complex to Diversity) compounds and 9 SAR (Structure Activity Relationship) compounds were synthesized utilizing the carbonyl group as a starting reaction point.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    脑中金属离子的代谢异常导致过量金属在细胞外和神经元间位置的积累,淀粉样β肽(Aβ)结合这些过渡金属,最终导致大脑中的Aβ聚集和严重的氧化应激。Aβ的聚集和氧化应激是诱发阿尔茨海默病(AD)的重要因素。金属螯合疗法是从Aβ-M物种中去除金属并减轻氧化应激的一种有前途的方法。因此,设计并合成了4种含有苯并噻唑部分的四氢salens。通过浊度测定法测定其在体外治疗阿尔茨海默病的生物学活性,BCA蛋白检测,MTT法检测DCFH-DA的荧光探针。结果与非特异性螯合剂(cliquinol,CQ)和非苯并噻唑官能化的四氢salens,结果表明,苯并噻唑功能化螯合剂在防止Cu2诱导的Aβ聚集方面具有更有效的生物活性,与cliquinol和非苯并噻唑功能化类似物相比,减弱了Aβ-Cu2物种介导的细胞毒性并降低了Cu2-Aβ处理的PC12细胞中活性氧(ROS)的水平。
    The dyshomeostasis of metal ions in the brain leads to the accumulation of excess metals in extracellular and inter-neuronal locations and the Amyloid β peptide (Aβ) binds these transition metals, which ultimately cause the Aβ aggregation and severe oxidative stress in the brain. The aggregation of Aβ and oxidative stress are important factors to trigger Alzheimer\'s disease (AD). Metal chelation therapy is a promising approach to removing metals from Aβ-M species and relieve the oxidative stress. Therefore, 4 tetrahydrosalens containing benzothiazole moiety were designed and synthesized. Their biological activities for Alzheimer\'s disease therapy in vitro were determined by Turbidity assay, BCA protein assay, MTT assay and fluorescent probe of DCFH-DA. The results were comparing with that of non-specific chelator (cliquinol, CQ) and non-benzothiazole functionalized tetrahydrosalens, the results demonstrated that benzothiazole functionalized chelators had more efficient bio-activities in preventing Cu2+-induced Aβ aggregation, attenuating cytotoxicity mediated by Aβ-Cu2+ species and decrease the level of reactive oxygen species (ROS) in Cu2+-Aβ treated PC12 cells than that of cliquinol and non-benzothiazole functionalized analogues.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    使用尼科氟洛尔作为先导化合物,我们通过用酰基取代酰胺氮原子上的甲基,设计并合成了一系列新的苯基吡唑类似物。生物测定结果表明,具有1-氰基环丙酰亚胺基团的化合物A12-A17具有出色的杀虫活性。化合物A12-A17对朱砂叶猴的LC50值范围为0.58至0.91mg/L。化合物A15对小菜蛾和桃树的LC50值为0.29和3.10mg/L,分别。分子对接表明化合物A15与γ-氨基丁酸受体的潜在结合相互作用。此外,密度泛函理论计算表明,1-氰基环丙酰亚胺结构可能对其生物活性至关重要。苯基吡唑衍生物,含有1-氰基环丙酰亚胺片段,作为潜在的杀虫剂有进一步发展的潜力。
    Using nicofluprole as the lead compound, we designed and synthesized a series of new phenylpyrazole analogues through substituting the methyl group on the nitrogen atom of the amide with an acyl group. Bioassay results showed that compounds A12-A17 with a 1-cyanocyclopropimide group exhibited outstanding insecticidal activity. The LC50 values for compounds A12-A17 against Tetranychus cinnabarinus ranged from 0.58 to 0.91 mg/L. Compound A15 showed an LC50 value of 0.29 and 3.10 mg/L against Plutella xylostella and Myzus persicae, respectively. Molecular docking indicated the potential binding interactions of compound A15 with a gamma-aminobutyric acid receptor. Additionally, density functional theory calculations implied that the 1-cyanocyclopropimide structure might be essential for its biological activity. Phenylpyrazole derivatives, containing a 1-cyanocyclopropimide fragment, have the potential for further development as potential insecticides.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    萜烯合酶(TS)通过一系列环化反应和碳骨架重排,将非手性异戊二烯基底物转化为具有多个立体中心的精细烃支架。该反应涉及高能碳阳离子中间体,其必须沿所需产物的途径被酶稳定。多种底物类似物已用于研究TS机制。本文将重点介绍一类用氟战略性地取代氢原子以抑制特定碳阳离子中间体生成的类似物。我们将探索类似物的合成和使用以研究TS机理。
    Terpene synthases (TS) transform achiral prenyl substrates into elaborate hydrocarbon scaffolds with multiple stereocenters through a series of cyclization reactions and carbon skeleton rearrangements. The reactions involve high-energy carbocation intermediates that must be stabilized by the enzyme along the pathway to the desired products. A variety of substrate analogs have been used to investigate TS mechanism. This article will focus on a class of analogs which strategically replace hydrogen atoms with fluorine to inhibit the generation of specific carbocation intermediates. We will explore the synthesis and use of the analogs to study TS mechanism.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    旨在发现有效和安全的非甾体抗炎药,一套新的1,2,4-三唑四氢呋喃异喹啉杂化物9a-g,合成11a-g和12a-g并评价为COX-1和COX-2的抑制剂。为了克服高选择性COX-2和非选择性COX-2抑制剂的不良反应,本研究的化合物的设计目的是获得中等选择性的COX-2抑制剂。在本研究中,化合物9e,9g和11f是对COX-2最有效的衍生物,IC50值为0.87、1.27和0.58µM,分别优于或与标准药物塞来昔布(IC50=0.82µM)相当,但选择性指数较低,如我们的目标设计所要求的。体内抗炎抑制试验结果表明,化合物9e,9g和11f在所有时间间隔显示出比塞来考昔更高的显著抗炎活性。此外,这些化合物显著降低了炎症介质PGE-2、TNF-α和IL-6的产生。化合物9e,与消炎痛相比,9g和11f具有安全的胃轮廓,此外,化合物11f(致溃疡指数=1.33)的溃疡性比安全的塞来昔布(致溃疡指数=3)低。此外,组织病理学研究显示,用化合物11f口服大鼠后,爪皮肤和胃粘膜的结构均正常。此外,在COX-1和COX-2上进行分子对接研究以研究化合物9e的结合模式,9g和11f两种同工酶。
    Aiming to discover effective and safe non-steroidal anti-inflammatory agents, a new set of 1,2,4-triazole tetrahydroisoquinoline hybrids 9a-g, 11a-g and 12a-g was synthesized and evaluated as inhibitors of COX-1 and COX-2. In order to overcome the adverse effects of highly selective COX-2 and non-selective COX-2 inhibitors, the compounds of this study were designed with the goal of obtaining moderately selective COX-2 inhibitors. In this study compounds 9e, 9g and 11f are the most effective derivatives against COX-2 with IC50 values 0.87, 1.27 and 0.58 µM, respectively which are better than or comparable to the standard drug celecoxib (IC50 = 0.82 µM) but with lower selectivity indices as required by our goal design. The results of the in vivo anti-inflammatory inhibition test revealed that compounds 9e, 9g and 11f displayed a higher significant anti-inflammatory activity than celecoxib at all-time intervals. In addition, these compounds significantly decreased the production of inflammatory mediators PGE-2, TNF-ɑ and IL-6. Compounds 9e, 9g and 11f had a safe gastric profile compared to indomethacin, also compound 11f (ulcerogenic index = 1.33) was less ulcerous than the safe celecoxib (ulcerogenic index = 3). Moreover, histopathological investigations revealed a normal architecture of both paw skin and gastric mucosa after oral treatment of rats with compound 11f. Furthermore, molecular docking studies were performed on COX-1 and COX-2 to study the binding pattern of compounds 9e, 9g and 11f on both isoenzymes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    通过多步合成制备了一类具有磺酰胺和酰胺官能团的新化合物作为潜在的阿尔茨海默病药物。热稳定性测量记录了200-220°C范围内的初始分解,接近熔点以上。测试最终化合物抑制乙酰胆碱酯酶和丁酰胆碱酯酶的能力,并通过亲脂性和亲水性基质片剂研究了所选化合物的体外溶出行为。所有九种测试的衍生物在抑制乙酰胆碱酯酶方面比临床上使用的卡巴拉汀更具活性。对获得的溶出曲线进行回归分析,并确定了pH值和释放机理的影响。一些物质显示出显着的生物活性,并成为进一步广泛研究的兴趣主题。
    A family of new compounds with sulfonamide and amide functional groups as potential Alzheimer\'s disease drugs were prepared by multistep synthesis. Thermal stability measurements recorded the initial decomposition in the range of 200-220°C, close above the melting point. The final compounds were tested for their ability to inhibit acetylcholinesterase and butyrylcholinesterase, and the in vitro dissolution behavior of selected compounds was studied through both lipophilic and hydrophilic matrix tablets. All nine tested derivatives were even more active in inhibiting acetylcholinesterase than the clinically used rivastigmine. Regression analysis of the obtained dissolution profiles was performed, and the effects of the pH and the release mechanism were determined. Some substances showed remarkable biological activity and became a subject of interest for further extensive study.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    合成了一系列双(吲哚基)-酰肼-腙衍生物,并使用1H-NMR和HRMS表征其结构。对制备的化合物的抗真菌活性进行了评价。,炭疽病-炭疽病。,灰霉病菌。:Fr.使用菌丝生长速率法和solaniKühn。初步的生物测定表明,大多数合成的化合物对四种测试的真菌都表现出抗真菌活性,并对S菌的菌丝体生长表现出明显的抑制作用。特别是,化合物3b,3c,和3k表现出对R.solani的显著抗真菌活性,EC50值为26.42、20.74和22.41μM,分别,优于阳性对照参钦霉素(47.18μM)和香芹酚(49.13μM)。
    A series of bis(indolyl)-hydrazide-hydrazone derivatives were synthesised, and their structures were characterised using 1H-NMR and HRMS. The antifungal activity of the prepared compounds was evaluated against Pyricularia oryzae Cav., Colletotrichum -gloeosporioides Penz., Botrytis cinerea Pers.: Fr. and Rhizoctonia solani Kühn using the mycelial growth rate method. The preliminary bioassays revealed that most of the synthesised compounds exhibited antifungal activity against the four tested fungi and displayed a remarkable inhibitory effect on the mycelium growth of R. solani. In particular, compounds 3b, 3c, and 3k demonstrated significant antifungal activity against R. solani, with EC50 values of 26.42, 20.74, and 22.41 μM, respectively, outperforming the positive control shenqinmycin (47.18 μM) and carvacrol (49.13 μM).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号